<DOC>
	<DOCNO>NCT01717911</DOCNO>
	<brief_summary>We find 6-month course insulin therapy short-term intensive insulin therapy could shorten period hyperglycemia preserve ß-cell function improve long-term glycemic control recently diagnose type 2 diabetes severe hyperglycemia ( &gt; 300 mg/dl , HBA1C level around 9-11 % ) previous study . We thus hypothesize 6-month course basal insulin therapy could also help preserve ß-cell function newly diagnose type 2 diabetes moderate hyperglycemia ( 200-300 mg/dl ) . This prospective study outpatient-based evaluate whether 6-month basal insulin therapy versus oral anti-diabetic treatment ( Metformin sitagliptin ) soon diagnosis type 2 diabetes moderate hyperglycemia ( 200-300 mg/dl ) associate well ß-cell function reservation . We skip short-term intensive admission course insulin therapy previous study newly diagnose type 2 diabetes severe hyperglycemia .</brief_summary>
	<brief_title>ß-Cell Function Glycemic Control Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia</brief_title>
	<detailed_description>ß-Cell dysfunction decrease insulin sensitivity main pathophysiological defect responsible development hyperglycemia . There progressive deterioration ß-cell function mass type 2 diabetic . Optimal metabolic control , especially early intensive glycemic control , play role prevention progressive ß-cell dysfunction possibly destruction ß-cells worsen diabetes . We find 6-month course insulin therapy short-term intensive insulin therapy could shorten period hyperglycemia preserve ß-cell function improve long-term glycemic control recently diagnose type 2 diabetes severe hyperglycemia ( &gt; 300 mg/dl , HBA1C level around 9-11 % ) previous study . We thus hypothesize 6-month course basal insulin therapy could also help preserve ß-cell function newly diagnose type 2 diabetes moderate hyperglycemia ( 200-300 mg/dl ) . This prospective study outpatient-based evaluate whether 6-month basal insulin therapy versus oral anti-diabetic treatment ( Metformin sitagliptin ) soon diagnosis type 2 diabetes moderate hyperglycemia ( 200-300 mg/dl ) associate well ß-cell function reservation . We skip short-term intensive admission course insulin therapy previous study newly diagnose type 2 diabetes severe hyperglycemia . This study also assess readily available parameter would predict patient achieve long-term successful glycemic control correction glucose toxicity . Our result provide evidence 6-month course basal insulin therapy could shorten exposure moderate hyperglycemia improve beta-cell function achieve long-term glycemic control .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>1 . Recently diagnose type 2 diabetic patient . 2 . Fasting plasma glucose 200300 mg/dl ( A1C level 7 % 10 % ) . 3 . Those age 30 80 year old inject insulin . 1 . Previous treat antidiabetic medication 2 . Pregnant nursing woman . 3 . Impaired liver function ( ALT &gt; 120 U/L ) 4 . Impaired renal function ( Serum creatinine &gt; 1.5 mg/dL male , &gt; 1.4 mg/dL female ) 5 . Recently suffer MI CVA . 6 . Patients acute intercurrent illness . 7 . 2hour Cpeptide level &lt; 1.8 ng/mL .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Newly diagnose type 2 diabetes</keyword>
	<keyword>Insulin , metformin , sitagliptin</keyword>
	<keyword>beta-cell function , glycemic control</keyword>
</DOC>